Skip to main content
Figure 3 | BMC Health Services Research

Figure 3

From: Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers

Figure 3

Chemotherapy utilization patterns, by tumor type. CYCL + DOX + VINC = cyclophosphamide + doxorubicin + vincristine; HCPCS = Healthcare Common Procedure Coding System; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer. Notes: Top 10 most frequently used regimens. Real-world data may show both approved and non-approved single agent and/or combination therapies (e.g. gemcitabine is indicated in combination with cisplatin for the first-line treatment of mNSCLC). Denominator for the estimated frequency distribution includes only patients initiating a HCPCS-identifiable first-, second-, or third-line chemotherapy regimen. For the esSCLC cohort, there were 4,256 patients initiating an HCPCS-identifiable first-line chemotherapy regimen, 1,824 patients initiating an HCPCS-identifiable second-line chemotherapy regimen, and 758 patients initiating an HCPCS-identifiable third-line chemotherapy regimen. For the mNSCLC cohort, there were 13,298 patients initiating an HCPCS-identifiable first-line chemotherapy regimen, 5,485 patients initiating an HCPCS-identifiable second-line chemotherapy regimen, and 2,108 patients initiating an HCPCS-identifiable third-line chemotherapy regimen.

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us